We think the market continues to underappreciate both Pfizer’s pipeline and recently launched drugs.
Eli Lilly reported strong second-quarter results, and we don’t see the delay of rheumatoid arthritis drug baricitinib as having a material impact.
The country's approval increases our conviction that the drug will eventually reach the U.S. market and strengthen Lilly's growth prospects and wide moat.
While the Republican-led Congress continues the push to repeal the Affordable Care Act, we still see challenges in passing any new legislation.
Amid advancements in new cancer drugs, we see Bristol-Myers and Roche as best positioned for investors.
Morningstar's Damien Conover expects steady growth for the wide-moat firm, which will likely lead to steady growth for the dividend.
While we remain bullish on Astra's prospects in immuno-oncology, we're concerned about the heavy patent losses facing the wide-moat firm.
We see the narrow-moat firm as slightly undervalued today.
Shares look undervalued amid a steady first quarter.
Shares look undervalued despite pessimistic Humira outlook.
Johnson & Johnson competitive position looks strong, but growth prospects don’t appear strong enough to support the current market price.
We think ACA repeal efforts are unlikely to lead to major legislative changes.
The company has established a strong presence in fast-growing emerging markets.
We think Roche, Pfizer, and Celgene are all well positioned due to their innovative oncology drugs.
We're bullish Merck’s immuno-oncology drug Keytruda, but weakness in the remaining parts of the company limit our enthusiasm at the current valuation.
The market is underappreciating the earnings growth potential of current drugs and the pipeline.
Even with Humira’s expected decline, we think the company has a narrow moat.
Steady growth in key divisions supports the company's wide economic moat.
We don't see any major shifts in U.S. drug prices over the next several years, but we expect changes to the Affordable Care Act.
Recent setbacks don't dent our conviction that Eli Lilly and Bristol-Myers' innovation is underappreciated by the market.
We have not made any changes to our fair value estimates of healthcare stocks.
We will likely lower the pharma giant’s fair value estimate slightly, but we still see shares of the wide-moat firm as attractive today.
Results for the company's third quarter were below expectations, but we continue to view it as undervalued.
Strong Keytruda outlook helps mitigate upcoming patent losses.
We think the market is not anticipating enough declines on several complex drugs due to generic and biosimilar pressures.
Opdivo setback aside, drugmakers Bristol, Merck, Roche and AstraZeneca are well positioned to reinforce their economic moats with transformative new immuno-oncology drugs.
Overblown concerns over drug pricing in the U.S. are creating attractive valuations for the more innovative drug companies.
Although some proposals could trim growth prospects, they shouldn’t have a major impact on more innovative drugs.
If the plan were to take shape, less innovative generic drugs and older branded drugs would be the likely targets for price controls.
Despite the high price paid, we don't expect any major changes in Pfizer's fair value estimate.
Anti-NGF drugs are a risky bet but could be a bonanza opportunity for Pfizer, Lilly, and Regeneron.
Bristol's poor trial results with key drug Opdivo open the door for Merck’s Keytruda to gain share.
Investors are underestimating the strong pricing environment for drugs that target unmet medical needs, like pain management.
We think the market underappreciates the depth of the firm’s pipeline and potential to increase margins.
The next generation of immunology drugs will help Eli Lilly navigate the shifting pharma landscape.
We plan to raise our fair value for the pharma giant after second-quarter results, but valuation remains rich.
Despite healthcare valuations increasing, we still see some stocks as undervalued, with opportunities in the drug and device areas.
We continue to think the shares are undervalued.
An anticipated slowdown in pharma giant’s drug business gives us some pause on the firm’s current valuation, but its long-term competitive advantages are intact.
New rules from the U.S. Treasury may put a damper on the Pfizer merger, but Allergan remains an attractively priced wide-moat company nonetheless.
Concern over unlikely U.S. drug pricing reforms has led to favorable valuations in healthcare.
Investors' concerns over the impacts of slowing global growth and drug pricing are overdone, leaving some quality names undervalued.
The pharma giant is mitigating its patent losses, and we think it's undervalued.
We think the market is underestimating the pharma giant’s long-term earnings potential.
Headwinds from the firm’s drug business shouldn't derail strong returns over the long run, says Morningstar’s Damien Conover.
While valuations in healthcare stocks have improved, we still see opportunities in these undervalued companies.
With manageable patent-loss exposures and strong pipelines, Big Pharma is the best positioned it has been since 2005.
The pharma megadeal strategically strengthens Pfizer with a lower tax rate and an increased growth profile, writes Morningstar’s Damien Conover.
We're increasing our fair value estimate on the pharma giant after a strong third-quarter update, says Morningstar's Damien Conover.
The wide-moat pharma firm’s third-quarter results were slightly ahead of our expectations, and we think the market continues to underappreciate the value of the company’s pipeline, writes Morningstar’s Damien Conover.